Abstract:Retinitis pigmentosa (RP) is the most genetically and phenotypically heterogeneous disorder, characterized by the progressive death of photoreceptor cells. In recent years, huge advances have been made in understanding the disease mechanisms, identifying causal genes, and developing therapeutic strategies for this disorder. This special issue updates the knowledge of RP and presents original clinical and experimental research. Photoreceptor cell death is known to be characterized at the early stage by caspase dependent or independent apoptosis and at late stage by necrosis, but the molecular mechanisms are not fully understood. In this special issue, S. R. Patnaik et al. review the functional role of RPGR protein complex in the pathogenesis of RP. Disease mechanisms are further elucidated in mouse (Q. Zheng et al.) and zebrafish models (Y. Liu et al. and S. Akhtar et al.). R. Migliorini et al. discuss RP associated syndromes, such as impaired ocular motility. E. Strobbe et al. report a correlation between ocular inflammation and endothelin (ET-1) plasma levels in early RP patients and suggest that anti-inflammatory therapy may slow the progression of RP. With the development of new technologies such as next generation sequencing (NGS), more and more mutant genes that cause retinal degenerative diseases have been found. B. Gong et al. reported here a recessive RDH12 mutation identified by exome sequencing in severe early onset RP patients, which further verifies the application of NGS for molecular diagnosis of RP. Meanwhile, many naturally occurring or genetically engineered animal models have shown gene mutations and phenotypes similar to human inherited retinal diseases, which has led to the development of a variety of therapeutic strategies for those inherited diseases regarded traditionally as incurable. Following the success of Leber congenital amaurosis 2 (LCA2) gene therapy clinical trials, more and more vector based gene therapy clinical trials have been performed on a variety of retinal conditions including RP with MERTK mutation. AAV-mediated gene replacement therapy shows great potential to treat patients in the early stage of the disease. Gene replacement therapy combined with other approaches like treatment with histone deacetylases inhibitors (reviewed by H. Zhang et al.) or antiapoptotic/inflammatory chemicals or natural products, which can extend the therapeutic window in middle to late stages of those patients, is a potentially promising strategy for improving photoreceptor function and significantly slowing the process of retinal degeneration. Cell replacement is a promising therapeutic strategy for RP. Successful cell replacement treatments have been done in RP animal models, providing hope for RP patients and their families. Chinese medicine has a long history in the treatment of RP; combinational treatment of Chinese medicine with Western medicine may further reduce the progression of RP (reviewed by J. Xu and Q. Peng). Xinhua Shu Ji-jing Pang Houbin Zhang David Mansfield

Pre-mRNA Processing Factors and Retinitis Pigmentosa: RNA Splicing and Beyond

Pre-mRNA Splicing and Retinitis Pigmentosa.

Retinitis Pigmentosa Alleles, in PRPF31 and PRPF6, Effects on Pre‐Messenger RNA Splicing

Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa

Human iPSC-derived RPE and retinal organoids reveal impaired alternative splicing of genes involved in pre-mRNA splicing in PRPF31 autosomal dominant retinitis pigmentosa

Disrupted alternative splicing for genes implicated in splicing and ciliogenesis causes PRPF31 retinitis pigmentosa

Retinal Pigment Epithelial Cells: The Unveiled Component in the Etiology of Prpf Splicing Factor-Associated Retinitis Pigmentosa

Temporal and tissue specific regulation of RP-associated splicing factor genes PRPF3, PRPF31 and PRPC8--implications in the pathogenesis of RP

PRPF mutations are associated with generalized defects in spliceosome formation and pre-mRNA splicing in patients with retinitis pigmentosa

Three gene-targeted mouse models of RNA splicing factor RP show late-onset RPE and retinal degeneration

Mutation spectrum of PRPF31, genotype-phenotype correlation in retinitis pigmentosa, and opportunities for therapy

Mutant Prpf31 causes pre-mRNA splicing defects and rod photoreceptor cell degeneration in a zebrafish model for Retinitis pigmentosa

Mutant PRPF8 Causes Widespread Splicing Changes in Spliceosome Components in Retinitis Pigmentosa Patient iPSC-Derived RPE Cells

A Precision Therapy Approach for Retinitis Pigmentosa 11 Using Splice-Switching Antisense Oligonucleotides to Restore the Open Reading Frame of PRPF31

Mutation analysis of pre-mRNA splicing genes in Chinese families with retinitis pigmentosa.

The splicing regulator Prp31 prevents retinal degeneration in Drosophila by regulating Rhodopsin levels

Alternative splicing and retinal degeneration

Microtubule modification defects underlie cilium degeneration in cell models of retinitis pigmentosa associated with pre-mRNA splicing factor mutations

Retinitis Pigmentosa: Disease Mechanisms, Diagnosis, and Therapies

Identification of a PRPF4 loss-of-function variant that abrogates U4/U6.U5 tri-snRNP integration and is associated with retinitis pigmentosa

Mutations in spliceosomal proteins and retina degeneration